NH125 kills methicillin-resistant Staphylococcus aureus persisters by lipid bilayer disruption

Future Medicinal Chemistry

Volumn 8, Issue 3, 2016, Pages 257-269

  Kim, Wooseong ^a   Fricke, Nico ^b   Conery, Annie L ^c,d   Fuchs, Beth Burgwyn ^a   Rajamuthiah, Rajmohan ^a,c   Jayamani, Elamparithi ^a,c   Vlahovska, Petia M ^b   Ausubel, Frederick M ^c,d   Mylonakis, Eleftherios ^a  

^a BROWN UNIVERSITY   (United States)

^b Brown University   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

antibiotics; giant unilamellar vesicle; MRSA; NH125; two component system

Indexed keywords

ANTIBIOTIC AGENT; CETALKONIUM CHLORIDE; CIPROFLOXACIN; GENTAMICIN; NH 125; OXACILLIN; UNCLASSIFIED DRUG; VANCOMYCIN; WALRYCIN B; ANTIINFECTIVE AGENT; IMIDAZOLE DERIVATIVE; LIPID BILAYER;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CELL PERMEABILIZATION; CONTROLLED STUDY; ENTEROBACTER AEROGENES; ENTEROCOCCUS FAECIUM; GRAM NEGATIVE BACTERIUM; HEMOLYSIS; HUMAN; HUMAN CELL; KLEBSIELLA PNEUMONIAE; LIPID BILAYER; MEMBRANE PERMEABILITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; CELL MEMBRANE PERMEABILITY; CHEMICAL STRUCTURE; CHEMISTRY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MICROBIAL SENSITIVITY TEST; STRUCTURE ACTIVITY RELATION;

ANTI-BACTERIAL AGENTS; CELL MEMBRANE PERMEABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; IMIDAZOLES; LIPID BILAYERS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84960111425     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.15.189     Document Type: Article

References (73)

1. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms and associated risks. Clin. Microbiol. Rev. 10(3), 505-520 (1997).
2. Gorwitz RJ, Kruszon-Moran D, McAllister SK et al. Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001-2004. J. Infect. Dis. 197(9), 1226-1234 (2008).
3. Wendlandt S, Schwarz S, Silley P. Methicillin-resistant Staphylococcus aureus: a food-borne pathogen? Annu. Rev. Food Sci. Technol. 4(1), 117-139 (2013).
4. David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin. Microbiol. Rev. 23(3), 616-687 (2010).
5. Chambers HF, DeLeo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat. Rev. Microbiol. 7(9), 629-641 (2009).
6. Otto M. Basis of virulence in community-associated methicillin-resistant Staphylococcus aureus. Annu. Rev. Microbiol. 64(1), 143-162 (2010).
7. Fischbach MA, Walsh C T. Antibiotics for emerging pathogens. Science. 325(5944), 1089-1093 (2009).
8. Keren I, Kaldalu N, Spoering A, Wang Y, Lewis K. Persister cells and tolerance to antimicrobials. FEMS Microbiol. Lett. 230(1), 13-18 (2004).
9. Allison KR, Brynildsen MP, Collins J J. Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature 473(7346), 216-220 (2011).
10. Conlon BP, Nakayasu ES, Fleck LE et al. Activated ClpP kills persisters and eradicates a chronic bioflm infection. Nature 503(7476), 365-370 (2013).
11. Kim W, Conery AL, Rajamuthiah R, Fuchs BB, Ausubel FM, Mylonakis E. Identifcation of an antimicrobial agent effective against Methicillin-resistant Staphylococcus aureus persisters using a fuorescence-based screening strategy. PLoS ONE. 10(6), e0127640 (2015).
12. LaFleur MD, Qi Q, Lewis K. Patients with long-term oral carriage harbor high-persister mutants of Candida albicans. Antimicrob. Agents Chemother. 54(1), 39-44 (2010).
13. Mulcahy LR, Burns JL, Lory S, Lewis K. Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fbrosis. J. Bacteriol. 192(23), 6191-6199 (2010).
14. Howden BP, Davies JK, Johnson PDR, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection and clinical implications. Clin. Microbiol. Rev. 23(1), 99-139 (2010).
15. Krell T, Lacal J, Busch A, Silva-Jiménez H, Guazzaroni M-E, Ramos JL. Bacterial sensor kinases: diversity in the recognition of environmental signals. Annu. Rev. Microbiol. 64(1), 539-559 (2010).
16. Gotoh Y, Eguchi Y, Watanabe T, Okamoto S, Doi A, Utsumi R. Two-component signal transduction as potential drug targets in pathogenic bacteria. Curr. Opin. Microbiol. 13(2), 232-239 (2010).
17. Martin PK, Li T, Sun D, Biek DP, Schmid MB. Role in cell permeability of an essential two-component system in Staphylococcus aureus. J. Bacteriol. 181(12), 3666-3673 (1999).
18. Sun J, Zheng L, Landwehr C, Yang J, Ji Y Identifcation of a novel essential two-component signal transduction system, YhcSR, in Staphylococcus aureus. J. Bacteriol. 187(22), 7876-7880 (2005).
19. Yamamoto K, Kitayama T, Ishida N et al. Identifcation and characterization of a potent antibacterial agent, NH125 against drug-resistant bacteria. Biosci. Biotechnol. Biochem. 64(4), 919-923 (2000).
20. Yamamoto K, Kitayama T, Minagawa S et al. Antibacterial agents that inhibit histidine protein kinase YycG of Bacillus subtilis. Biosci. Biotechnol. Biochem. 65(10), 2306-2310 (2001).
21. Watanabe T, Hashimoto Y, Yamamoto K et al. Isolation and characterization of inhibitors of the essential histidine kinase, YycG in Bacillus subtilis and Staphylococcus aureus. J. Antibiot. 56(12), 1045-1052 (2003).
22. Okada A, Igarashi M, Okajima T et al. Walkmycin B targets WalK (YycG), a histidine kinase essential for bacterial cell growth. J. Antibiot. 63(2), 89-94 (2010).
23. Gotoh Y, Doi A, Furuta E et al. Novel antibacterial compounds specifcally targeting the essential WalR response regulator. J. Antibiot. 63(3), 127-134 (2010).
24. Huang R-Z, Zheng L-K, Liu H-Y et al. Thiazolidione derivatives targeting the histidine kinase YycG are effective against both planktonic and bioflm-associated Staphylococcus epidermidis. Acta Pharmacologica Sinica. 33(3), 418-425 (2012).
25. Watanabe T, Igarashi M, Okajima T et al. Isolation and characterization of signermycin B, an antibiotic that targets the dimerization domain of histidine kinase WalK. Antimicrob. Agents Chemother. 56(7), 3657-3663 (2012).
26. Igarashi M, Watanabe T, Hashida T et al. Waldiomycin, a novel WalK-histidine kinase inhibitor from Streptomyces sp. MK844-mF10. J. Antibiot. 66(8), 459-464 (2013).
27. Walde P, Cosentino K, Engel H, Stano P. Giant vesicles: preparations and applications. Chembiochem 11(7), 848-865 (2010).
28. Kahya N. Protein-protein and protein-lipid interactions in domain-assembly: lessons from giant unilamellar vesicles. Biochim. Biophys. Acta 1798(7), 1392-1398 (2010).
29. Baba T, Takeuchi F, Kuroda M et al. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 359(9320), 1819-1827 (2002).
30. Garsin DA, Sifri CD, Mylonakis E et al. A simple model host for identifying Gram-positive virulence factors. Proc. Natl Acad. Sci. USA 98(19), 10892-10897 (2001).
31. Junior JC, Fuchs BB, Sabino CP et al. Photodynamic and antibiotic therapy impair the pathogenesis of Enterococcus faecium in a whole animal insect model. PLoS ONE 8(2), e55926 (2013).
32. Smith MG, Gianoulis TA, Pukatzki S et al. New insights into Acinetobacter baumannii pathogenesis revealed by high-density pyrosequencing and transposon mutagenesis. Genes Dev. 21(5), 601-614 (2007).
33. Rahme LG, Stevens EJ, Wolfort SF, Shao J, Tompkins RG, Ausubel FM. Common virulence factors for bacterial pathogenicity in plants and animals. Science 268(5219), 1899-1902 (1995).
34. Rajamuthiah R, Jayamani E, Conery AL et al. A defensin from the model beetle Tribolium castaneum acts synergistically with telavancin and daptomycin against multidrug resistant Staphylococcus aureus. PLoS ONE 10(6), e0128576 (2015).
35. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard 9th edition. CLSI document M07-A9. Wayne, PA, USA.
36. Angelova MI, Soléau S, Méléard P, Faucon F, Bothorel P. Preparation of giant vesicles by external AC electric felds. Kinetics and applications. Prog. Colloid Polym. Sci. 89, 127-131 (1992).
37. Chen Y-F, Sun T-L, Sun Y, Huang HW. Interaction of daptomycin with lipid bilayers: a lipid extracting effect. Biochemistry 53(33), 5384-5392 (2014).
38. Mertins O, Dimova R. Insights on the interactions of chitosan with phospholipid vesicles. Part II: Membrane stiffening and pore formation. Langmuir 29(47), 14552-14559 (2013).
39. Dubrac S, Msadek T. Identifcation of genes controlled by the essential YycG/YycF two-component system of Staphylococcus aureus. J. Bacteriol. 186(4), 1175-1181 (2004).
40. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J. Infect. Dis. 197(8), 1079-1081 (2008).
41. Howell A, Dubrac S, Noone D, Varughese KI, Devine K. Interactions between the YycFG and PhoPR two-component systems in Bacillus subtilis: the PhoR kinase phosphorylates the non-cognate YycF response regulator upon phosphate limitation. Mol. Microbiol. 59(4), 1199-1215 (2006).
42. Gueriri I, Bay S, Dubrac S, Cyncynatus C, Msadek T. The Pta-AckA pathway controlling acetyl phosphate levels and the phosphorylation state of the DegU orphan response regulator both play a role in regulating Listeria monocytogenes motility and chemotaxis. Mol. Microbiol. 70(6), 1342-1357 (2008).
43. McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action and resistance. Clin. Microbiol. Rev. 12(1), 147-179 (1999).
44. Gilbert P, Moore LE. Cationic antiseptics: diversity of action under a common epithet. J. Appl. Microbiol. 99(4), 703-715 (2005).
45. Tamba Y, Yamazaki M. Single giant unilamellar vesicle method reveals effect of antimicrobial peptide magainin 2 on membrane permeability. Biochemistry 44(48), 15823-15833 (2005).
46. Ambroggio EE, Separovic F, Bowie JH, Fidelio GD, Bagatolli LA. Direct Visualization of Membrane Leakage Induced by the Antibiotic Peptides: Maculatin, Citropin and Aurein. Biophys. J. 89(3), 1874-1881 (2005).
47. Lee C-C, Sun Y, Qian S, Huang HW. Transmembrane pores formed by human antimicrobial peptide LL-37. Biophys. J. 100(7), 1688-1696 (2011).
48. Wang Y, Corbitt TS, Jett SD et al. Direct visualization of bactericidal action of cationic conjugated polyelectrolytes and oligomers. Langmuir 28(1), 65-70 (2012).
49. Ganewatta MS, Chen YP, Wang J et al. Bio-inspired resin acid-derived materials as anti-bacterial resistance agents with unexpected activities. Chem. Sci. 5(5), 2011-2016 (2014).
50. Caillon L, Killian JA, Lequin O, Khemtémourian L. Biophysical investigation of the membrane-disrupting mechanism of the antimicrobial and amyloid-like peptide dermaseptin S9. PLoS ONE 8(10), e75528 (2013).
51. Cadwallader DE, Ansel HC. Hemolysis of erythrocytes by antibacterial preservatives II. Quaternary ammonium salts. J. Pharm. Sci. 54(7), 1010-1012 (1965).
52. Cha SH, Lee JS, Oum BS, Kim CD. Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro. Clin. Exp. Ophthalmol. 32(2), 180-184 (2004).
53. Ho C-Y, Wu M-C, Lan M-Y, Tan C-T, Yang A-H. In vitro effects of preservatives in nasal sprays on human nasal epithelial cells. Am. J. Rhinol. 22(2), 125-129 (2008).
54. Lewis K. Persister cells. Annu. Rev. Microbiol. 64(1), 357-372 (2010).
55. Helaine S, Kugelberg E. Bacterial persisters: formation, eradication and experimental systems. Trends Microbiol. 22(7), 417-424 (2014).
56. Spoering AL, Lewis K. Bioflms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials. J. Bacteriol. 183(23), 6746-6751 (2001).
57. Dubrac S, Boneca IG, Poupel O, Msadek T New insights into the WalK/WalR (YycG/YycF) essential signal transduction pathway reveal a major role in controlling cell wall metabolism and bioflm formation in Staphylococcus aureus. J. Bacteriol. 189(22), 8257-8269 (2007).
58. Huang R-Z, Zheng L-K, Liu H-Y et al. Thiazolidione derivatives targeting the histidine kinase YycG are effective against both planktonic and bioflm-associated Staphylococcus epidermidis. Acta Pharmacol. Sin. 33(3), 418-425 (2012).
59. Hurdle JG, O'Neill AJ, Chopra I, Lee RE. Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nat. Rev. Microbiol. 9(1), 62-75 (2011).
60. Straus SK, Hancock REW Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim. Biophys. Acta 1758(9), 1215-1223 (2006).
61. Figueroa DA, Mangini E, Amodio-Groton M et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin. Infect. Dis. 49(2), 177-180 (2009).
62. Kostrominova TY, Coleman S, Oleson FB, Faulkner JA, Larkin LM. Effect of daptomycin on primary rat muscle cell cultures in vitro. In vitro Cell. Dev. Biol.-Animal 46(7), 613-618 (2010).
63. Koh J-J, Qiu S, Zou H et al. Rapid bactericidal action of alpha-mangostin against MRSA as an outcome of membrane targeting. Biochim. Biophys. Acta 1828(2), 834-844 (2013).
64. Zou H, Koh J-J, Li J et al. Design and synthesis of amphiphilic xanthone-based, membrane-targeting antimicrobials with improved membrane selectivity. J. Med. Chem. 56(6), 2359-2373 (2013).
65. Müller G, Kramer A. Biocompatibility index of antiseptic agents by parallel assessment of antimicrobial activity and cellular cytotoxicity. J. Antimicrob. Chemother. 61(6), 1281-1287 (2008).
66. Dimova R, Aranda S, Bezlyepkina N, Nikolov V, Riske KA, Lipowsky R. A practical guide to giant vesicles. Probing the membrane nanoregime via optical microscopy. J. Phys. Condens. Matter. 18(28), S1151-S1176 (2006).
67. Sudbrack TP, Archilha NL, Itri R, Riske KA. Observing the solubilization of lipid bilayers by detergents with optical microscopy of GUVs. J. Phys. Chem. B. 115(2), 269-277 (2011).
68. Lichtenberg D, Ahyayauch H, Goñi FM. The mechanism of detergent solubilization of lipid bilayers. Biophys. J. 105(2), 289-299 (2013).
69. Kragh-Hansen U, le Maire M, MØller JV. The mechanism of detergent solubilization of liposomes and protein-containing membranes. Biophys. J. 75(6), 2932-2946 (1998).
70. Stuart MCA, Boekema EJ. Two distinct mechanisms of vesicle-to-micelle and micelle-to-vesicle transition are mediated by the packing parameter of phospholipid-detergent systems. Biochim. Biophys. Acta 1768(11), 2681-2689 (2007).
71. Cócera M, Lopez O, Coderch L, Parra JL, la Maza de A. Infuence of the level of ceramides on the permeability of stratum corneum lipid liposomes caused by a C12-betaine/sodium dodecyl sulfate mixture. Int. J. Pharm. 183(2), 165-173 (1999).
72. Heerklotz H. Membrane stress and permeabilization induced by asymmetric incorporation of compounds. Biophys. J. 81(1), 184-195 (2001).
73. Roth BL, Poot M, Yue ST, Millard PJ. Bacterial viability and antibiotic susceptibility testing with SYTOX green nucleic acid stain. Appl. Environ. Microbiol. 63(6), 2421-2431 (1997).